202 related articles for article (PubMed ID: 31749810)
21. Reduction in CD16/CD56 and CD16/CD3/CD56 Natural Killer Cells in Coronary Artery Disease.
Jabir NR; Firoz CK; Ahmed F; Kamal MA; Hindawi S; Damanhouri GA; Almehdar HA; Tabrez S
Immunol Invest; 2017 Jul; 46(5):526-535. PubMed ID: 28414590
[TBL] [Abstract][Full Text] [Related]
22. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals.
Tarazona R; Casado JG; Delarosa O; Torre-Cisneros J; Villanueva JL; Sanchez B; Galiani MD; Gonzalez R; Solana R; Peña J
J Clin Immunol; 2002 May; 22(3):176-83. PubMed ID: 12078859
[TBL] [Abstract][Full Text] [Related]
23. Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer.
Koo KC; Shim DH; Yang CM; Lee SB; Kim SM; Shin TY; Kim KH; Yoon HG; Rha KH; Lee JM; Hong SJ
PLoS One; 2013; 8(11):e78049. PubMed ID: 24223759
[TBL] [Abstract][Full Text] [Related]
24. The Role of Circulating CD16+CD56+ Natural Killer Cells in the Screening, Diagnosis, and Staging of Colorectal Cancer before Initial Treatment.
Cui F; Qu D; Sun R; Tao H; Si J; Xu Y
Dis Markers; 2019; 2019():7152183. PubMed ID: 31636738
[TBL] [Abstract][Full Text] [Related]
25. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation.
Dulphy N; Haas P; Busson M; Belhadj S; Peffault de Latour R; Robin M; Carmagnat M; Loiseau P; Tamouza R; Scieux C; Rabian C; Di Santo JP; Charron D; Janin A; Socié G; Toubert A
J Immunol; 2008 Aug; 181(3):2227-37. PubMed ID: 18641363
[TBL] [Abstract][Full Text] [Related]
26. Changes in subset distribution and impaired function of circulating natural killer cells in patients with colorectal cancer.
Zu S; Lu Y; Xing R; Chen X; Zhang L
Sci Rep; 2024 May; 14(1):12188. PubMed ID: 38806640
[TBL] [Abstract][Full Text] [Related]
27. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
28. Increased frequency of ILT2-expressing CD56(dim)CD16(+) NK cells correlates with disease severity of pulmonary tuberculosis.
Wang X; Meng X; Zheng Y; Jiang J; Yang B; Liu Y; Zhai F; Cheng X
Tuberculosis (Edinb); 2014 Sep; 94(5):469-74. PubMed ID: 24909369
[TBL] [Abstract][Full Text] [Related]
29. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling.
Hanna J; Bechtel P; Zhai Y; Youssef F; McLachlan K; Mandelboim O
J Immunol; 2004 Dec; 173(11):6547-63. PubMed ID: 15557145
[TBL] [Abstract][Full Text] [Related]
30. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.
Oppenheim DE; Spreafico R; Etuk A; Malone D; Amofah E; Peña-Murillo C; Murray T; McLaughlin L; Choi BS; Allan S; Belousov A; Passioukov A; Gerdes C; Umaña P; Farzaneh F; Ross P
Br J Cancer; 2014 Mar; 110(5):1221-7. PubMed ID: 24496456
[TBL] [Abstract][Full Text] [Related]
31. Proliferative and cytotoxic capabilities of CD16+CD56- and CD16+/-CD56+ natural killer cells.
Søndergaard SR; Ullum H; Pedersen BK
APMIS; 2000 Dec; 108(12):831-7. PubMed ID: 11252817
[TBL] [Abstract][Full Text] [Related]
32. Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status.
Chalan P; Bijzet J; Kroesen BJ; Boots AM; Brouwer E
J Rheumatol; 2016 Jun; 43(6):1008-16. PubMed ID: 27036380
[TBL] [Abstract][Full Text] [Related]
33. An increase in the absolute count of CD56dimCD16+CD69+ NK cells in the peripheral blood is associated with a poorer IVF treatment and pregnancy outcome.
Thum MY; Bhaskaran S; Abdalla HI; Ford B; Sumar N; Shehata H; Bansal AS
Hum Reprod; 2004 Oct; 19(10):2395-400. PubMed ID: 15319390
[TBL] [Abstract][Full Text] [Related]
34. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer.
Yin M; Di G; Bian M
Int Immunopharmacol; 2018 Nov; 64():333-339. PubMed ID: 30243069
[TBL] [Abstract][Full Text] [Related]
35. CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.
Morandi F; Horenstein AL; Chillemi A; Quarona V; Chiesa S; Imperatori A; Zanellato S; Mortara L; Gattorno M; Pistoia V; Malavasi F
J Immunol; 2015 Aug; 195(3):965-72. PubMed ID: 26091716
[TBL] [Abstract][Full Text] [Related]
36. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
37. Circulating NK cells and their subsets in Behçet's disease.
Hasan MS; Ryan PL; Bergmeier LA; Fortune F
Clin Exp Immunol; 2017 May; 188(2):311-322. PubMed ID: 28170096
[TBL] [Abstract][Full Text] [Related]
38. Adoptive immunotherapy with double-bright (CD56
Silla L; Valim V; Pezzi A; da Silva M; Wilke I; Nobrega J; Vargas A; Amorin B; Correa B; Zambonato B; Scherer F; Merzoni J; Sekine L; Huls H; Cooper LJ; Paz A; Lee DA
Br J Haematol; 2021 Dec; 195(5):710-721. PubMed ID: 34490616
[TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.
Frankel TL; Burns W; Riley J; Morgan RA; Davis JL; Hanada K; Quezado M; Rosenberg SA; Royal RE
Cancer Immunol Immunother; 2010 Dec; 59(12):1757-69. PubMed ID: 20734041
[TBL] [Abstract][Full Text] [Related]
40. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation.
Romagnani C; Juelke K; Falco M; Morandi B; D'Agostino A; Costa R; Ratto G; Forte G; Carrega P; Lui G; Conte R; Strowig T; Moretta A; Münz C; Thiel A; Moretta L; Ferlazzo G
J Immunol; 2007 Apr; 178(8):4947-55. PubMed ID: 17404276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
